Icon Plc Receives Consensus Rating of “Buy” from Analysts (NASDAQ:ICLR)
Icon Plc (NASDAQ:ICLR) has received a consensus recommendation of “Buy” from the eleven brokerages that are currently covering the company, AnalystRatingsNetwork reports. One investment analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $56.01.
Icon Plc (NASDAQ:ICLR) opened at 51.06 on Friday. Icon Plc has a 52 week low of $35.33 and a 52 week high of $53.50. The stock’s 50-day moving average is $49.94 and its 200-day moving average is $46.01. The company has a market cap of $3.160 billion and a P/E ratio of 23.28.
Icon Plc (NASDAQ:ICLR) last released its earnings data on Wednesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.06. The company had revenue of $376.00 million for the quarter, compared to the consensus estimate of $376.89 million. During the same quarter in the previous year, the company posted $0.43 earnings per share. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. Analysts expect that Icon Plc will post $2.64 EPS for the current fiscal year.
A number of research firms have recently commented on ICLR. Analysts at Zacks upgraded shares of Icon Plc from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 13th. They now have a $54.10 price target on the stock. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Icon Plc in a research note on Monday, August 4th. They now have a $60.00 price target on the stock, up previously from $53.00. Finally, analysts at SunTrust reiterated a “buy” rating on shares of Icon Plc in a research note on Thursday, July 31st. They now have a $70.00 price target on the stock, up previously from $56.00.
ICON public limited company (NASDAQ:ICLR) is a contract research organization (CRO) providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.